A Phase 2 interventional study of Carboplatin and Pemetrexed in Lung Cancer, Small-cell Lung Cancer and Non Small Cell Lung Cancer, sponsored by Fox Chase Cancer Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-22.
Sponsored by Fox Chase Cancer Center · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 156 studies testing carboplatin in Lung Neoplasms — 9 open to participants now, 18 under way, 3 of them phase 3. Carboplatin · Lung Neoplasms.
Among the 156 studies testing carboplatin in Lung Neoplasms, this one is the 14th largest by planned enrollment of the 137 interventional ones that give a count, is one of 3 that started in 2023, is one of 102 in phase 2, reaches primary completion later than 12 of the 17 other live ones, and was the 151st registered.
5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.
Browse Lung Neoplasms studies →9 of the 156 studies testing carboplatin in Lung Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Latin American Cooperative Oncology Group · Sites in Brazil
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 70+
Centre Leon Berard · Sites in France, Reunion
Ages 18+
Rutgers, The State University of New Jersey · Sites in United States
Ages 18+
AstraZeneca · Sites in United States, Belgium, Canada and 9 more countries
Ages 18–95
By country, each count listing its studies:
Carboplatin: first FDA approval 1989 (PARAPLATIN). What it is approved for, and how studies give it, is on its page →
Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
156 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 115 · Phase 3 27 · Phase 4 2
First in 1996; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 280 is above the median of 60 across 3,668 interventional studies indexed under Lung Neoplasms.
Median enrollment 49 across the 137 interventional studies. Of the 113 that completed or were terminated, 48 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 156 have an industry lead sponsor. The 10 most frequent:
Fox Chase Cancer Center is the lead sponsor of 216 studies on the registry; 29 are open to participants now.
Of its 16 completed or terminated interventional studies of FDA-regulated products, 9 (56%) have results posted.
16 studies in Lung Neoplasms by Fox Chase Cancer Center: 2 open now, 2 under way, none of them phase 3. Of 13 finished, 2 (15%) have results posted.
Among the 16 studies in Lung Neoplasms by Fox Chase Cancer Center, this one is the 3rd largest by planned enrollment of the 12 interventional ones that give a count, is the only one that started in 2023, is one of 7 in phase 2, and was the 16th registered.
Fox Chase Cancer Center’s Lung Neoplasms studies by the year they started, since 1998.
2 of the studies testing carboplatin in Lung Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03793179Phase 3National Cancer Institute (NCI)Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer | 2027-09-30 |
| NCT05358548Rutgers, The State University of New JerseyATATcH Alternating Treatment Plans for Advanced Cancer | 2027-05-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 156 studies testing carboplatin in Lung Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Fox Chase Cancer Center’s 16 in Lung Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is an open-label, non-randomized, single-center, phase II study to evaluate the efficacy, toxicity and, tolerability of pre-specified dose attenuated chemotherapy regimens in lung cancer patients with comorbidities.
This is an open-label, non-randomized, single-center, phase II study to evaluate the efficacy, toxicity and, tolerability of pre-specified dose attenuated chemotherapy regimens in lung cancer patients with comorbidities. The investigator will indicate the rationale(s) for dose modification based on the subgroups of patients listed in the protocol. Patients may fit into multiple subgroups and this is accounted for in the prospectively defined dose reduction level as listed in the protocol. Prespecified doses by chemotherapeutic agent and dose level adjustment based on patient characteristics and comorbidities are listed in the protocol. Analyses will be stratified by treatment group 1-3 based on the treating physician's selected therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Carboplatin · Drug: Pemetrexed · Drug: Paclitaxel · Drug: Nab paclitaxel · Drug: Docetaxel · Drug: Gemcitabine · Drug: Etoposide · Drug: Irinotecan · Drug: Topotecan · Drug: Lurbinectedin
Drug: Carboplatin · Drug: Pemetrexed · Drug: Paclitaxel · Drug: Nab paclitaxel · Drug: Docetaxel · Drug: Gemcitabine · Drug: Etoposide · Drug: Irinotecan · Drug: Topotecan · Drug: Lurbinectedin
Drug: Carboplatin · Drug: Pemetrexed · Drug: Paclitaxel · Drug: Nab paclitaxel · Drug: Docetaxel · Drug: Gemcitabine · Drug: Etoposide · Drug: Irinotecan · Drug: Topotecan · Drug: Lurbinectedin
Standard of care chemotherapy regimen
Standard of care chemotherapy regimen
Standard of care chemotherapy regimen
Standard of care chemotherapy regimen
Standard of care chemotherapy regimen
Standard of care chemotherapy regimen
Standard of care chemotherapy regimen
Standard of care chemotherapy regimen
Standard of care chemotherapy regimen
Standard of care chemotherapy regimen
Objective response rate (ORR)
To estimate the ORR including confirmed complete response (CR) and partial response (PR) rates in each treatment group 1-3
Time frame: 6 years
Frequency of adverse events
To evaluate the frequency and severity of toxicities attributed to chemotherapy administered on trial. To evaluate the tolerability of prospectively dose attenuated chemotherapy Evaluate toxicity by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events version 5.0 criteria (CTCAE 5.0) by Treatment Group in all patients who received at least one dose of treatment on trial. Tolerability will be defined as receiving two or more chemotherapy cycles with no more than a one week delay (due to treatment related toxicity) during the initial treatment period (first four cycles), delivered with pre-specified dose modifications to the cytotoxic component(s) of standard regimens for NSCLC and SCLC. Proportions of adverse events will be tabulated and organized by grade (all grade and grade 3 or higher).
Time frame: 6 years
Progression free survival (PFS)
To evaluate PFS in each treatment group. PFS is defined as the time from treatment initiation until documented disease progression, clinical progression, death, or the end of follow-up, whichever occurs first. Patients who are still alive and progression free at last follow-up will be considered censored at the time of last tumor assessment
Time frame: 6 years
Overall survival (OS)
To evaluate overall survival (OS) in each treatment group. OS is defined as the time from treatment initiation until death. Patients who are still alive at end of follow-up will be considered censored.
Time frame: 6 years
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2023 (actual). Primary completion is estimated for Aug 2028, 65 months after the start.
Of 285 non-industry phase 2 interventional studies under Lung Neoplasms, half reached primary completion within 72 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 113. This study's planned 65 months is close to that.
Counting every sponsor, half of 362 studies reached it within 65 months; a quarter within 34 and three quarters within 102.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Carboplatin · Pemetrexed · Paclitaxel · Albumin-Bound Paclitaxel · Docetaxel · Gemcitabine · Etoposide · Irinotecan · Topotecan · PM 01183